1. Home
  2. Bills
  3. H.R. 2430

H.R. 2430 · 115th Congress · 2017–2018

FDA Reauthorization Act of 2017

H.R. 2430 in the 115th Congress (2017–2018) became law — introduced on May 16, 2017, sponsored by Greg Walden with 3 co-sponsors. Congress held 2 roll call votes on it.

During the 115th Congress (2017–2018), Donald Trump was president, and Republicans held majorities in both the House and Senate.

Status
Became law
Introduced
May 16, 2017
Co-sponsors
3
Policy area
Health
Public law
Public Law 115-52

What it does

FDA Reauthorization Act of 2017 TITLE I--FEES RELATING TO DRUGS Prescription Drug User Fee Amendments of 2017 (Sec. 102) This bill amends the Federal Food, Drug, and Cosmetic Act to extend through FY2022 and revise Food and Drug Administration (FDA) user fees for brand name drugs. User fees are eliminated for supplemental new drug applications and drug manufacturing facilities.

Summary by the nonpartisan Congressional Research Service.

Sponsor

Greg Walden (R-OR). Co-sponsors: 2 Democrats, 1 Republican.

Where it stands

  • IntroducedMay 16, 2017
  • Passed the HouseJul 12, 2017
  • Passed the SenateAug 3, 2017
  • Sent to the PresidentAug 7, 2017
  • Became lawAug 18, 2017

Latest action: Signed by President. (Aug 18, 2017)

How Congress voted

  • On Passage of the Bill
    Senate · Aug 3, 2017 · Bill Passed
    94–1
  • On the Cloture Motion
    Senate · Aug 3, 2017 · Cloture Motion Agreed to
    96–1

Every roll call vote on this bill

More bills from Greg Walden in the 115th Congress

Other Health bills in the 115th Congress

Committees

More

From GovInfo bill records, Congressional Research Service summaries, Voteview roll calls and lobbying reports.

Cite or embed this page

Capitol Receipts, “H.R. 2430 (115th Congress): FDA Reauthorization Act of 2017,” https://www.capitolreceipts.com/bill/115-hr-2430/fda-reauthorization-act-of-2017 (accessed 2026-10-16).

Open the interactive version ›